Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, particularly autoimmune pulmonary alveolar proteinosis (aPAP)
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, particularly autoimmune pulmonary alveolar proteinosis (aPAP). Their lead product candidate, MOLBREEVI, is an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development.